Ig-like fusion proteins and use thereof
AssigneeCanopy Immuno-Therapeutics Ltd.
InventorsKfir OVED, Galit DENKBERG, Sharon REEF, Yelena PINZUR
Life of this patent
Estimating the term…
Abstract
Compositions comprising a fragment of a first human receptor target of myasthenia gravis autoantibodies or an analog or derivative thereof and a fragment of a second human protein receptor of myasthenia gravis autoantibodies or an analog or derivative thereof are provided. Pharmaceutical compositions comprising the composition, nucleic acid systems encoding the polypeptides of the composition and methods of treatment and determining suitability for treatment using the composition; as well as methods of producing the composition are also provided.
Claims66
A composition, comprising a protein complex comprising:
- a. a first polypeptide chain comprising a fragment of a first human acetylcholine receptor subunit or an analog or derivative thereof and a first dimerization domain, and
- b. a second polypeptide chain comprising a fragment of a second human acetylcholine receptor subunit or an analog or derivative thereof and a second dimerization domain,
- and wherein said first and second subunits are different subunits, said analog or derivative thereof comprises at least 85% identity to said human protein and said first and second dimerization domains are configured to dimerize with each other.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A polypeptide comprising a fragment of a first human acetylcholine receptor subunit comprising at least one mutation that decreases aggregation of the fragment, wherein said fragment is selected from:
- a. a fragment of ACHRA and comprises a mutation selected from:
- deletion of N141, F100G, W149R, V155A, Y93F, Y93H, Y93R and a combination thereof within a wild-type AChRa comprising SEQ ID NO:
- 1 or a AChRa with increased solubility comprising SEQ ID NO:
- 131;
- b. a fragment of ACHRG and comprises a mutation selected from:
- M84S, Y105E, Y117E, Y117R, and a combination thereof within a wild-type AChRa comprising SEQ ID NO:
- 6 or a AChRa with increased solubility comprising SEQ ID NO:
- 133;
- and
- c. a fragment of ACHRD and comprises a mutation selected from:
- C108A, C108I, Y119R, deletion of N141, L151E and a combination thereof within a wild-type AChRa comprising SEQ ID NO:
- 8 or a AChRa with increased solubility comprising SEQ ID NO:
- 134.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.